Cargando…

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation

PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehret, Felix, Wolfgang, Josy, Allwohn, Luisa, Onken, Julia, Wasilewski, David, Roohani, Siyer, Oertel, Joachim, Zips, Daniel, Kaul, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369398/
https://www.ncbi.nlm.nih.gov/pubmed/37502699
http://dx.doi.org/10.1016/j.ctro.2023.100653
_version_ 1785077751728832512
author Ehret, Felix
Wolfgang, Josy
Allwohn, Luisa
Onken, Julia
Wasilewski, David
Roohani, Siyer
Oertel, Joachim
Zips, Daniel
Kaul, David
author_facet Ehret, Felix
Wolfgang, Josy
Allwohn, Luisa
Onken, Julia
Wasilewski, David
Roohani, Siyer
Oertel, Joachim
Zips, Daniel
Kaul, David
author_sort Ehret, Felix
collection PubMed
description PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. MATERIALS AND METHODS: GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. RESULTS: A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. CONCLUSION: The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis.
format Online
Article
Text
id pubmed-10369398
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103693982023-07-27 Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation Ehret, Felix Wolfgang, Josy Allwohn, Luisa Onken, Julia Wasilewski, David Roohani, Siyer Oertel, Joachim Zips, Daniel Kaul, David Clin Transl Radiat Oncol Original Research Article PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. MATERIALS AND METHODS: GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. RESULTS: A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. CONCLUSION: The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis. Elsevier 2023-06-13 /pmc/articles/PMC10369398/ /pubmed/37502699 http://dx.doi.org/10.1016/j.ctro.2023.100653 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Ehret, Felix
Wolfgang, Josy
Allwohn, Luisa
Onken, Julia
Wasilewski, David
Roohani, Siyer
Oertel, Joachim
Zips, Daniel
Kaul, David
Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title_full Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title_fullStr Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title_full_unstemmed Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title_short Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
title_sort outcomes of isocitrate dehydrogenase wild type glioblastoma after re-irradiation
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369398/
https://www.ncbi.nlm.nih.gov/pubmed/37502699
http://dx.doi.org/10.1016/j.ctro.2023.100653
work_keys_str_mv AT ehretfelix outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT wolfgangjosy outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT allwohnluisa outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT onkenjulia outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT wasilewskidavid outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT roohanisiyer outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT oerteljoachim outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT zipsdaniel outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation
AT kauldavid outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation